Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Population
2.2. Questionnaire Survey about Booster Vaccine Acceptance
2.3. Serological Assay
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Johns Hopkins University & Medicine. Coronavirus Resource Center. Available online: https://coronavirus.jhu.edu/map.html (accessed on 9 February 2022).
- Lin, C.; Tu, P.; Beitsch, L.M. Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review. Vaccines 2020, 9, 16. [Google Scholar] [CrossRef] [PubMed]
- Drugs and Lactation Database (LactMed) [Internet]. National Library of Medicine (US): Bethesda, MD, USA, 2006. COVID-19 Vaccines. Available online: https://www.ncbi.nlm.nih.gov/books/NBK565969/ (accessed on 9 February 2022).
- Sallam, M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines 2021, 9, 160. [Google Scholar] [CrossRef] [PubMed]
- Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. Author Correction: A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2021, 27, 354. [Google Scholar] [CrossRef] [PubMed]
- WHO. Ten Threats to Global Health 2019. Available online: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 (accessed on 9 February 2022).
- Fisher, K.A.; Bloomstone, S.J.; Walder, J.; Crawford, S.; Fouayzi, H.; Mazor, K.M. Attitudes Toward a Potential SARS-CoV-2 Vaccine. Ann. Intern. Med. 2020, 173, 964–973. [Google Scholar] [CrossRef]
- Levin, E.G.; Lustig, Y.; Cohen, C.; Fluss, R.; Indenbaum, V.; Amit, S.; Doolman, R.; Asraf, K.; Mendelson, E.; Ziv, A.; et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N. Engl. J. Med. 2021, 385, e84. [Google Scholar] [CrossRef]
- WHO. Interim Statement on Booster Doses for COVID-19 Vaccination. Available online: https://www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination---update-22-december-2021 (accessed on 20 March 2022).
- Joshi, A.; Kaur, M.; Kaur, R.; Grover, A.; Nash, D.; El-Mohandes, A. Predictors of COVID-19 Vaccine Acceptance, Intention, and Hesitancy: A Scoping Review. Front. Public Health 2021, 9, 698111. [Google Scholar] [CrossRef]
- Wang, Y.; Liu, Y. Multilevel determinants of COVID-19 vaccination hesitancy in the United States: A rapid systematic review. Prev. Med. Rep. 2021, 25, 101673. [Google Scholar] [CrossRef]
- Folcarelli, L.; Miraglia Del Giudice, G.; Corea, F.; Angelillo, I.F. Intention to Receive the COVID-19 Vaccine Booster Dose in a University Community in Italy. Vaccines 2022, 10, 146. [Google Scholar] [CrossRef]
- Rzymski, P.; Poniedziałek, B.; Fal, A. Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland. Vaccines 2021, 9, 1286. [Google Scholar] [CrossRef]
- Yadete, T.; Batra, K.; Netski, D.M.; Antonio, S.; Patros, M.J.; Bester, J.C. Assessing Acceptability of COVID-19 Vaccine Booster Dose among Adult Americans: A Cross-Sectional Study. Vaccines 2021, 9, 1424. [Google Scholar] [CrossRef]
- Klugar, M.; Riad, A.; Mohanan, L.; Pokorná, A. COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study. Vaccines 2021, 9, 1437. [Google Scholar] [CrossRef] [PubMed]
- Pal, S.; Shekhar, R.; Kottewar, S.; Upadhyay, S.; Singh, M.; Pathak, D.; Kapuria, D.; Barrett, E.; Sheikh, A.B. COVID-19 Vaccine Hesitancy and Attitude toward Booster Doses among US Healthcare Workers. Vaccines 2021, 9, 1358. [Google Scholar] [CrossRef] [PubMed]
- Corporation, J.B. Novel Coronaviruses Data for Fukushima Prefecture. Available online: https://www3.nhk.or.jp/news/special/coronavirus/data/pref/fukushima.html (accessed on 9 February 2022).
- Inc., N. COVID-19 Vaccination Status in Japan Charted. Available online: https://vdata.nikkei.com/newsgraphics/coronavirus-japan-vaccine-status/ (accessed on 4 February 2022).
- Kobashi, Y.; Nishikawa, Y.; Kawamura, T.; Kodama, T.; Shimazu, Y.; Obara, D.; Zhao, T.; Tsubokura, M. Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study. Int. Immunopharmacol. 2021, 98, 107884. [Google Scholar] [CrossRef] [PubMed]
- Kobashi, Y.; Shimazu, Y.; Nishikawa, Y.; Kawamura, T.; Kodama, T.; Obara, D.; Tsubokura, M. The difference between IgM and IgG antibody prevalence in different serological assays for COVID-19; lessons from the examination of healthcare workers. Int. Immunopharmacol. 2021, 92, 107360. [Google Scholar] [CrossRef]
- Shenzhen YHLO Biotech Co., Ltd. iFlash-SARS-CoV-2 IgG-S. 2020. Available online: https://www.mblbio.com/bio/g/dtl/P/?pcd=YH-C86095G (accessed on 9 February 2022).
- Shenzhen YHLO Biotech Co., Ltd. iFlash-2019-nCoV NAb. 2021. Available online: https://ruo.mbl.co.jp/bio/e/dtl/P/?pcd=YH-C86109 (accessed on 9 February 2022).
- Bish, A.; Yardley, L.; Nicoll, A.; Michie, S. Factors associated with uptake of vaccination against pandemic influenza: A systematic review. Vaccine 2011, 29, 6472–6484. [Google Scholar] [CrossRef]
- Gagneux-Brunon, A.; Detoc, M.; Bruel, S.; Tardy, B.; Rozaire, O.; Frappe, P.; Botelho-Nevers, E. Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: A cross-sectional survey. J. Hosp. Infect. 2021, 108, 168–173. [Google Scholar] [CrossRef]
- Al-Mohaithef, M.; Padhi, B.K. Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey. J. Multidiscipl. Healthc. 2020, 13, 1657–1663. [Google Scholar] [CrossRef]
- Malik, A.A.; McFadden, S.M.; Elharake, J.; Omer, S.B. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine 2020, 26, 100495. [Google Scholar] [CrossRef]
- Wang, Q.; Yang, L.; Jin, H.; Lin, L. Vaccination against COVID-19: A systematic review and meta-analysis of acceptability and its predictors. Prev. Med. 2021, 150, 106694. [Google Scholar] [CrossRef]
- Krishnamoorthy, Y.; Kannusamy, S.; Sarveswaran, G.; Majella, M.G.; Sarkar, S.; Narayanan, V. Factors related to vaccine hesitancy during the implementation of Measles-Rubella campaign 2017 in rural Puducherry-A mixed-method study. J. Family Med. Prim. Care 2019, 8, 3962–3970. [Google Scholar] [CrossRef]
- Agrawal, A.; Kolhapure, S.; Di Pasquale, A.; Rai, J.; Mathur, A. Vaccine Hesitancy as a Challenge or Vaccine Confidence as an Opportunity for Childhood Immunisation in India. Infect. Dis. Ther. 2020, 9, 421–432. [Google Scholar] [CrossRef] [PubMed]
- Su, Z.; Wen, J.; Abbas, J.; McDonnell, D.; Cheshmehzangi, A.; Li, X.; Ahmad, J.; Šegalo, S.; Maestro, D.; Cai, Y. A race for a better understanding of COVID-19 vaccine non-adopters. Brain Behav. Immun. 2020, 9, 100159. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Jing, R.; Lai, X.; Zhang, H.; Lyu, Y.; Knoll, M.D.; Fang, H. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. Vaccines 2020, 8, 482. [Google Scholar] [CrossRef] [PubMed]
- Harapan, H.; Wagner, A.L.; Yufika, A.; Winardi, W.; Anwar, S.; Gan, A.K.; Setiawan, A.M.; Rajamoorthy, Y.; Sofyan, H.; Mudatsir, M. Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia. Front. Public Health 2020, 8, 381. [Google Scholar] [CrossRef]
- Dror, A.A.; Eisenbach, N.; Taiber, S.; Morozov, N.G.; Mizrachi, M.; Zigron, A.; Srouji, S.; Sela, E. Vaccine hesitancy: The next challenge in the fight against COVID-19. Eur. J. Epidemiol. 2020, 35, 775–779. [Google Scholar] [CrossRef]
- Wang, W.; Wu, Q.; Yang, J.; Dong, K.; Chen, X.; Bai, X.; Chen, X.; Chen, Z.; Viboud, C.; Ajelli, M.; et al. Global, regional, and national estimates of target population sizes for covid-19 vaccination: Descriptive study. BMJ 2020, 371, m4704. [Google Scholar] [CrossRef]
- Peretti-Watel, P.; Seror, V.; Cortaredona, S.; Launay, O.; Raude, J.; Verger, P.; Fressard, L.; Beck, F.; Legleye, S.; L’Haridon, O.; et al. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. Lancet Infect. Dis. 2020, 20, 769–770. [Google Scholar] [CrossRef]
- Bell, S.; Clarke, R.; Mounier-Jack, S.; Walker, J.L.; Paterson, P. Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. Vaccine 2020, 38, 7789–7798. [Google Scholar] [CrossRef]
- Rhodes, A.; Hoq, M.; Measey, M.-A.; Danchin, M. Intention to vaccinate against COVID-19 in Australia. Lancet Infect. Dis. 2021, 21, e110. [Google Scholar] [CrossRef]
- Kajiwara, S.; Akiyama, N.; Ohta, M. Intentions Regarding COVID-19 Vaccination in Females Aged 15&49 Years. Vaccines 2022, 10, 336. [Google Scholar]
- Bellomo, N.; Bingham, R.; Chaplain, M.A.J.; Dosi, G.; Forni, G.; Knopoff, D.A.; Lowengrub, J.; Twarock, R.; Virgillito, M.E. A multiscale model of virus pandemic: Heterogeneous interactive entities in a globally connected world. Math. Models Methods Appl. Sci. 2020, 30, 1591–1651. [Google Scholar] [CrossRef] [PubMed]
Accept Vaccine | Hesitate over Vaccine | Total | |
---|---|---|---|
Age ** (mean [SD]) | 52.8 [18.9] | 44.0 [19.0] | 52.6 [19.3] |
Sex | |||
Male | 998 (41.8) | 20 (38.5) | 1018 (41.7) |
IgG antibody titer *** (median (25th 75th)) | 319.6 (171.7–571.3) | 549.9 (446.0–724.1) | 324.9 (173.2–576.3) |
Municipality * | |||
Hirata | 1343 (56.3) | 37 (71.2) | 1380 (56.6) |
Soma | 464 (19.4) | 5 (9.6) | 469 (19.2) |
Minamisoma | 580 (24.3) | 10 (19.2) | 590 (24.2) |
Adverse reaction | |||
Local pain | 1358 (57.0) | 24 (46.2) | 1382 (56.8) |
Over 37.5 °C fever * | 676 (28.4) | 21 (40.4) | 697 (28.7) |
Fatigue | 1195 (50.2) | 28 (53.9) | 1223 (50.3) |
Headache ** | 646 (27.1) | 22 (42.3) | 668 (27.4) |
Joint pain | 728 (30.6) | 18 (34.6) | 746 (30.7) |
Diarrhea | 53 (2.2) | 2 (3.9) | 55 (2.3) |
Nausea *** | 87 (3.7) | 87 (17.3) | 96 (3.9) |
Dizziness | 102 (4.3) | 3 (5.8) | 105 (4.3) |
n (%) | |
---|---|
Reasons to accept the third vaccination (n = 2387) | |
Necessary for infection control | 1952 (81.8) |
Vaccines are highly effective | 1128 (47.3) |
Adverse reactions are not a major concern | 647 (27.1) |
The second vaccination is not effective enough | 494 (20.7) |
Considering the number of people infected with the COVID-19 | 325 (13.6) |
Vaccine is safe | 311 (13) |
Access to vaccination sites is good | 300 (12.6) |
Low antibody levels | 280 (11.7) |
I have a chronic disease | 181 (7.6) |
No work shift | 118 (4.9) |
Reasons to hesitate over the third vaccination (n = 52) | |
Worried about adverse reactions | 30 (57.7) |
Two doses of vaccine are sufficient | 13 (25.0) |
Efficacy is unknown | 10 (19.2) |
Worried about long term effects | 8 (15.4) |
Too much trouble | 4 (7.7) |
The number of people infected with COVID-19 is small. | 4 (7.7) |
Antibody titers are high | 3 (5.8) |
Other methods of infection control are sufficient | 2 (3.8) |
I can’t take a day off work or school. | 1 (1.9) |
I don’t have a chronic disease. | 0 (0.0) |
B (se) | OR (95% CI) | p-Value | |
---|---|---|---|
Age | −0.021 | 0.98 (0.96–1.00) | 0.030 |
Sex (base: male) | 0.066 | 1.07 (0.60–1.92) | 0.82 |
Number of whole-body adverse reactions | 0.049 | 1.05 (0.87–1.27) | 0.61 |
IgG antibody titer | 0.920 | 2.52 (1.27–4.99) | 0.008 |
Municipality (base: Hirata) | |||
Soma | −1.060 | 0.35 (0.13–0.91) | 0.031 |
Minamisoma | −0.580 | 0.56 (0.28–1.15) | 0.113 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yoshida, M.; Kobashi, Y.; Kawamura, T.; Shimazu, Y.; Nishikawa, Y.; Omata, F.; Zhao, T.; Yamamoto, C.; Kaneko, Y.; Nakayama, A.; et al. Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey. Vaccines 2022, 10, 515. https://doi.org/10.3390/vaccines10040515
Yoshida M, Kobashi Y, Kawamura T, Shimazu Y, Nishikawa Y, Omata F, Zhao T, Yamamoto C, Kaneko Y, Nakayama A, et al. Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey. Vaccines. 2022; 10(4):515. https://doi.org/10.3390/vaccines10040515
Chicago/Turabian StyleYoshida, Makoto, Yurie Kobashi, Takeshi Kawamura, Yuzo Shimazu, Yoshitaka Nishikawa, Fumiya Omata, Tianchen Zhao, Chika Yamamoto, Yudai Kaneko, Aya Nakayama, and et al. 2022. "Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey" Vaccines 10, no. 4: 515. https://doi.org/10.3390/vaccines10040515